natgillin/translations-raw huggingface dataset:
oestrogens and progestagens, saluretics, thiazide diuretics, thyroid stimulating agents, glucocorticoids, phenothiazine derivatives, chlorpromazine, adrenaline and sympathicomimetics, nicotinic acid (high doses) and nicotinic acid derivatives, laxatives (long-term use), phenytoin, diazoxide, glucagon, barbiturates and rifampicin.
estrogeni i progestageni, saluretici, tiazidski diuretici, lijekovi koji stimuliraju štitnjaču, glukokortikosteroidi, derivati fenotiazina, klorpromazin, adrenalin i simpatomimetici, nikotinska kiselina (visoke doze) i derivati nikotinske kiseline, laksativi (dugotrajno uzimanje), fenitoin, diazoksid, glukagon, barbiturati i rifampicin, acetozolamid.
not known not known rash2
nepoznato nepoznato svrbež2
Nausea, vomiting and epigastric pain may occur.
Mogu se javiti mučnina, povraćanje i bol u epigastriju.
Glimepiride increases very rapidly the number of active glucose transport molecules in the plasma membranes of muscle and fat cells, resulting in stimulated glucose uptake.
Glimepirid vrlo brzo povećava broj molekula za aktivni transport glukoze u plazmatskim membranama mišićnih i masnih stanica, što rezultira stimulacijom unosa glukoze iz krvi u stanice.
Musculoskeletal and connective tissue disorders bone fracture7
Poremećaji mišićno-koštanog sustava i vezivnog tkiva prijelomi kosti7
- Hypersensitivity to the active substances or to any of the excipients listed in section 6.1, or other sulphonylureas or sulphonamides - Cardiac failure or history of cardiac failure (NYHA stages I to IV) - Current bladder cancer or a history of bladder cancer - Uninvestigated macroscopic haematuria - Hepatic impairment - Type 1 diabetes mellitus - Diabetic coma - Diabetic ketoacidosis - Severe renal function disorders (creatinine clearance < 30 ml/min) - Pregnancy - Breast-feeding (see section 4.6)
- preosjetljivost na djelatne tvari ili neke od pomoćnih tvari navedenih u dijelu 6.1 ili na druge sulfonilureje ili sulfonamide - zatajenje srca ili anamneza zatajenja srca (NYHA stadiji I do IV) - prisutni ili preboljeni karcinom mokraćnog mjehura - neispitana makroskopska hematurija - oštećenje jetre - šećerna bolest tipa 1 - dijabetička koma - dijabetička ketoacidoza - teški poremećaji funkcije bubrega (klirens kreatinina < 30 ml/min) - trudnoća - dojenje (vidjeti dio 4.6)
Skin and subcutaneous tissue disorders sweating uncommon hypersensitivity to light very rare very rare urticaria2
Poremećaji kože i potkožnog tkiva znojenje manje često preosjetljivost na svjetlo vrlo rijetko vrlo rijetko urtikarija2
In clinical trials with pioglitazone the incidence of elevations of ALT greater than three times the upper limit of normal was equal to placebo but less than that seen in metformin or sulphonylurea comparator groups.
10 U kliničkim ispitivanjima pioglitazona, povišenje ALT-a više od tri puta iznad gornje granice normale bilo je jednako često kao uz placebo, ali manje često nego u skupinama koje su kao komparator primale metformin ili sulfonilureju.
Takeda GmbH Production Site Oranienburg Lehnitzstrasse 70 - 98 16515 Oranienburg, Germany
Lehnitzstrasse 70 - 98 16515 Oranienburg, Njemačka
Blurred vision due to swelling (or fluid) at the back of the eye (macular oedema) has also been reported in patients taking Tandemact (frequency cannot be estimated from the available data).
U bolesnika koji su uzimali Tandemact zabilježen je i zamagljen vid zbog oticanja (ili nakupljanja tekućine) na stražnjoj strani oka (makularni edem) (učestalost se ne može procijeniti iz dostupnih podataka).
9 In active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2 - 3 kg over one year.
U ispitivanjima kontroliranima aktivnim komparatorom, prosječno povećanje tjelesne težine uz monoterapiju pioglitazonom iznosilo je 2-3 kg tijekom jedne godine.
Metabolism and nutrition disorders hypoglycaemia uncommon appetite increased uncommon
Poremećaji metabolizma i prehrane hipoglikemija manje često pojačan apetit manje često
Rare changes in haematology have been observed with glimepiride treatment (see section 4.8).
Uz liječenje glimepiridom zabilježene su rijetke hematološke promjene (vidjeti dio 4.8).
If a pregnancy occurs, treatment with Tandemact should be discontinued.
U slučaju trudnoće, liječenje lijekom Tandemact treba prekinuti.
Glimepiride is transferred to the placenta.
Glimepirid prelazi u posteljicu.
In a 20-week study, as well as reducing fasting triglycerides, pioglitazone reduced post prandial hypertriglyceridaemia through an effect on both absorbed and hepatically synthesised triglycerides.
U ispitivanju u trajanju od 20 tjedana pioglitazon je uz sniženje triglicerida natašte snizio i postprandijalnu hipertrigliceridemiju putem učinka kako na apsorbirane trigliceride, tako i na one sintetizirane u jetri.
In controlled clinical trials the incidence of reports of heart failure with pioglitazone treatment was the same as in placebo, metformin and sulphonylurea treatment groups, but was increased when used in combination therapy with insulin.
U kontroliranim kliničkim ispitivanjima zatajenje srca bilo je zabilježeno jednako često u skupinama liječenima pioglitazonom kao i u skupinama koje su primale placebo, metformin ili sulfonilureju, ali bilo je češće uz kombiniranu terapiju s inzulinom.
Thiazolidinediones act primarily by reducing insulin resistance and sulphonylureas primarily by inducing insulin release from pancreatic beta cells.
Tiazolidindioni prvenstveno djeluju tako da smanjuju inzulinsku rezistenciju, dok sulfonilureje prvenstveno induciraju oslobađanje inzulina iz beta stanica gušterače.
Adverse reactions reported in double-blind studies and post marketing experience are listed below as MedDRA preferred term by system organ class and absolute frequency.
Nuspojave zabilježene u dvostruko slijepim ispitivanjima i razdoblju nakon stavljanja lijeka u promet navedene su niže prema standardnim MedDRA pojmovima, klasifikaciji organskih sustava i učestalosti.
If you experience this symptom for the first time, talk to your doctor as soon as possible.
Ako prvi put dobijete ovaj simptom, obratite se čim prije svom liječniku.
Weakening of the blood-glucose-lowering effect and, thus raised blood glucose levels may occur when one of the following active substances is taken, for example:
Može nastupiti slabljenje učinka na sniženje glukoze u krvi, a time i povišenje razine glukoze u krvi, kad se uzimaju sljedeće djelatne tvari kao što su:
Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including pioglitazone.
U razdoblju nakon stavljanja lijeka u promet zabilježeni su slučajevi novonastalog ili pogoršanje postojećeg dijabetičkog makularnog edema sa smanjenjem oštrine vida kod uzimanja tiazolidindiona, uključujući i pioglitazon.
The following medicines may decrease the blood sugar lowering effect of Tandemact.
Sljedeći lijekovi mogu smanjiti učinak lijeka Tandemact na sniženje šećera u krvi.
Similar changes were seen in metformin (haemoglobin 3-4% and haematocrit 3.6-4.1% relative reductions) and to a lesser extent sulphonylurea and insulin (haemoglobin 1-2% and haematocrit 1-3.2% relative reductions) treated patients in comparative controlled trials with pioglitazone.
U komparativnim kliničkim ispitivanjima pioglitazona slične su promjene viđene u bolesnika liječenih metforminom (relativno sniženje hemoglobina za 3-4% i hematokrita za 3,6-4,1%) te u manjoj mjeri u onih liječenih sulfonilurejom i inzulinom (relativno sniženje hemoglobina za 1-2% i hematokrita za
The following medicines can increase the blood sugar lowering effect of Tandemact.
Sljedeći lijekovi mogu pojačati učinak lijeka Tandemact na sniženje šećera u krvi.
Glimepiride acts mainly by stimulating insulin release from pancreatic beta cells.
Glimepirid djeluje uglavnom tako da potiče oslobađanje inzulina iz beta stanica gušterače.
The observed excess risk of fractures for women on pioglitazone in this study is therefore 0.5 fractures per 100 patient years of use.
Opaženo povećanje rizika od prijeloma u žena koje su u ovom ispitivanju uzimale pioglitazon stoga je iznosilo 0,5 prijeloma na 100 bolesnik-godina primjene.
This is similar to that seen in a sulphonylurea active comparator group.
To je slično povećanju tjelesne težine u skupini koja je primala sulfonilureju kao aktivni komparator.
QUALITATIVE AND QUANTITATIVE COMPOSITION Tandemact 30 mg/2 mg tablets
KVALITATIVNI I KVANTITATIVNI SASTAV Tandemact 30 mg/2 mg tablete
The symptoms may include cold sweat, tiredness, headache, rapid heartbeat, hunger pangs, irritability, nervousness or nausea.
Simptomi mogu uključivati hladan znoj, umor, glavobolju, ubrzan rad srca, jaku glad, razdražljivost, nervozu ili mučninu.
How to store Tandemact
Kako čuvati Tandemact
A higher rate of fractures was observed in women taking pioglitazone (2.6%) versus comparator (1.7%).
Opažena incidencija prijeloma bila je veća u žena koje su uzimale pioglitazon (2,6%) nego u onih koje su uzimale komparator (1,7%).
- allergic reactions including allergic shock - feeling sick (nausea), vomiting and diarrhoea - stomach ache - abdominal pressure - feeling of fullness in the stomach - sensitivity to light - decrease in salt (sodium) concentrations in the blood
Vrlo rijetko (može se javiti u do 1 na 10 000 osoba) - bolest jetre - alergijske reakcije uključujući alergijski šok - mučnina, povraćanje i proljev - bol u trbuhu - pritisak u trbuhu - osjećaj punoće u želucu - osjetljivost na svjetlost - snižene koncentracije soli (natrija) u krvi
This can lead to a risk of hypoglycaemia (low blood sugar): - gemfibrozil and fibrates (to lower high cholesterol level) - insulin, metformin or other medicines to treat diabetes mellitus - phenylbutazone, azapropazone, oxyphenbutazone, aspirin-like medicines (to treat pain and inflammation) - long acting sulphonamides, tetracyclines, chloramphenicol, fluconazole, miconazole,
To može stvoriti rizik od hipoglikemije (nizak šećer u krvi): - gemfibrozil i fibrati (za snižavanje povišene razine kolesterola) - inzulin, metformin ili drugi lijekovi za liječenje šećerne bolesti - fenilbutazon, azapropazon, oksifenbutazon, lijekovi slični aspirinu (za liječenje bola i upale) - dugodjelujući sulfonamidi, tetraciklini, kloramfenikol, flukonazol, mikonazol, kinoloni,
In toxicology studies, plasma volume expansion with haemodilution, anaemia, and reversible eccentric cardiac hypertrophy was consistently apparent after repeated dosing of mice, rats, dogs, and monkeys.
U toksikološkim su ispitivanjima nakon ponovljenog doziranja u miševa, štakora, pasa i majmuna dosljedno opažene ekspanzija volumena plazme sa hemodilucijom, anemija i reverzibilna ekscentrična hipertrofija srca.
Marketing authorisation holder Takeda Pharma A/S Dybendal Alle 10
Nositelj odobrenja za stavljanje lijeka u promet Takeda Pharma A/S
Tandemact is contra-indicated during breast-feeding (see section 4.3).
Tandemact je kontraindiciran tijekom dojenja (vidjeti dio 4.3).
The symptoms may include cold sweat, tiredness, headache, rapid heartbeat, hunger pangs, irritability, nervousness, nausea, coma or convulsion.
Simptomi mogu uključivati hladan znoj, umor, glavobolju, ubrzan rad srca, jaku glad, razdražljivost, nervozu, mučninu, komu ili konvulzije.
Hypersensitivity reactions of the skin may occur as itching, rash, and urticaria.
Kožne reakcije preosjetljivosti mogu nastati u obliku svrbeža, osipa i urtikarije.
Each tablet contains approximately 177 mg lactose monohydrate (see section 4.4).
Jedna tableta sadrži približno 177 mg laktoze hidrata (vidjeti dio 4.4).
Allergic reactions have been reported with frequency not known (cannot be estimated from the available data) in patients taking Tandemact.
Kod bolesnika koji su uzimali Tandemact zabilježene su alergijske reakcije s nepoznatom učestalosti (ne može se procijeniti iz dostupnih podataka).
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Obavijestite svog liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove, zato što neki lijekovi mogu oslabiti ili pojačati učinke lijeka Tandemact na razinu šećera u krvi.
In animals, glimepiride is excreted in milk.
Glimepirid se izlučuje u mlijeko životinja.
There was no relevant accumulation.
Nije bilo znatnijeg nakupljanja lijeka.
Elderly Steady state pharmacokinetics are similar in patients age 65 and over and young subjects.
Farmakokinetika u stanju dinamičke ravnoteže u bolesnika u dobi od 65 ili više godina slična je onoj u mlađih osoba.
It is recommended, therefore, that patients treated with Tandemact undergo periodic monitoring of liver enzymes.
Stoga se u bolesnika liječenih lijekom Tandemact preporučuje povremeno određivati jetrene enzime.
Each tablet contains approximately 214 mg lactose monohydrate (see section 4.4).
Jedna tableta sadrži približno 214 mg laktoze hidrata (vidjeti dio 4.4).
Each tablet contains approximately 125 mg lactose monohydrate (see section 4.4).
Jedna tableta sadrži približno 125 mg laktoze hidrata (vidjeti dio 4.4).
There have been rare reports of elevated liver enzymes and hepatocellular dysfunction during post-marketing experience with pioglitazone and glimepiride (see section 4.8).
Nakon stavljanja pioglitazona i glimepirida u promet zabilježeni su rijetki slučajevi povišenja jetrenih enzima i poremećaja hepatocelularne funkcije (vidjeti dio 4.8).
4.7 Effects on ability to drive and use machines Tandemact has minor influence on the ability to drive and use machines.
Tandemact malo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Pioglitazone should be used with caution during concomitant administration of cytochrome P450 2C8 inhibitors (e.g. gemfibrozil) or inducers (e.g. rifampicin).
Pioglitazon se mora primjenjivati s oprezom tijekom istodobne primjene inhibitora (npr. gemfibrozil) ili induktora (npr. rifampicin) citokroma P450 2C8.
3 Postmarketing reports of hypersensitivity reactions in patients treated with pioglitazone have been reported.
3 Nakon stavljanja lijeka na tržište, kod bolesnika liječenih pioglitazonom prijavljeni su slučajevi reakcija preosjetljivosti.
Tandemact 45 mg/4 mg tablets
Tandemact 45 mg/4 mg tablete
- headache - inflammation of the sinuses (sinusitis) - vertigo - abnormal vision - sweating - tiredness - difficulty sleeping (insomnia) - decreased blood sugar - sugar in urine - proteins in urine - increased appetite - increase of an enzyme called lactic dehydrogenase (LDH)
Manje često (mogu se pojaviti u do 1 na 100 osoba) - glavobolja - upala sinusa (sinusitis) - osjećaj vrtnje (vrtoglavica) - poremećaj vida - znojenje - umor - poteškoće sa spavanjem (nesanica) - snižen šećer u krvi - šećer u mokraći - proteini u mokraći - pojačan apetit - povišenje enzima laktat dehidrogenaze (LDH)
It is not known whether pioglitazone is secreted in human milk.
Nije poznato izlučuje li se pioglitazon u majčino mlijeko.
An increased incidence in bone fractures in women was seen in a pooled analysis of adverse reactions reports of bone fracture from randomised, controlled, double blind clinical trials (see section 4.8).
Analiza objedinjenih podataka o prijelomima kostiju kao nuspojavi u randomiziranim, kontroliranim, dvostruko slijepim kliničkim ispitivanjima (vidjeti dio 4.8) pokazala je povećanu incidenciju prijeloma kostiju u žena.
Hypoglycaemia (low blood sugar) has been reported uncommonly (may affect up to 1 in 100 people) in patients taking Tandemact.
U bolesnika koji uzimaju Tandemact manje često je zabilježena hipoglikemija (snižen šećer u krvi) (može se javiti u do 1 na 100 osoba).
Co-administration of pioglitazone with rifampicin (an inducer of cytochrome P450 2C8) is reported to result in a 54% decrease in AUC of pioglitazone.
Zabilježeno je da istovremena primjena pioglitazona s rifampicinom (induktor citokroma P450 2C8) rezultira sniženjem AUC-a pioglitazona za 54%.
INFORMATION IN BRAILLE Tandemact 45 mg/4 mg
16. PODACI NA BRAILLEOVOM PISMU Tandemact 45 mg/4 mg
General disorders and administration site conditions oedema8
Opći poremećaji i reakcije na mjestu primjene edemi8
Co-administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) is reported to result in a 3-fold increase in AUC of pioglitazone.
Zabilježeno je da istovremena primjena pioglitazona s gemfibrozilom (inhibitorom citokroma P450 2C8) rezultira trostrukim povećanjem AUC-a pioglitazona.
not known not known itching2
nepoznato nepoznato osip2
The following data are findings in studies performed with pioglitazone or glimepiride individually.
Sljedeći podaci dobiveni su iz ispitivanja posebno pioglitazona i posebno glimepirida.
A higher number of bone fractures was seen in patients, particularly women taking pioglitazone.
U bolesnika, naročito u žena koje uzimaju pioglitazon primijećen je veći broj prijeloma kostiju.
INFORMATION IN BRAILLE Tandemact 30 mg/2 mg
16. PODACI NA BRAILLEOVOM PISMU Tandemact 30 mg/2 mg
Frequency of adverse reactions Pioglitazone Glimepiride Tandemact
Učestalost nuspojava Pioglitazon Glimepirid
Tandemact 30 mg/4 mg tablets
Tandemact 30 mg/4 mg tablete
HDL-cholesterol levels were observed as compared to placebo, with small, but not clinically significant increases in LDL-cholesterol levels.
U većini kliničkih ispitivanja opaženo je sniženje ukupnih triglicerida i slobodnih masnih kiselina u plazmi te povišenje razine HDL-kolesterola u usporedbi s placebom, uz malo, ali ne i klinički značajno povišenje razine LDL-kolesterola.
Tandemact 30 mg/2 mg tablets Tandemact 30 mg/4 mg tablets Tandemact 45 mg/4 mg tablets pioglitazone/glimepiride
Tandemact 30 mg/4 mg tablete Tandemact 45 mg/4 mg tablete pioglitazon/glimepirid
This check should be repeated at intervals.
Tu ćete pretragu redovito ponavljati.
INFORMATION IN BRAILLE Tandemact 30 mg/4 mg
16. PODACI NA BRAILLEOVOM PISMU Tandemact 30 mg/4 mg
Nervous system disorders dizziness common hypo-aesthesia common common headache uncommon insomnia uncommon uncommon
Poremećaji živčanog sustava omaglica često hipoestezija često često glavobolja manje često nesanica manje često manje često
Pharmacotherapeutic group: Drugs used in diabetes, combinations of oral blood glucose lowering drugs; ATC code: A10BD06.
Farmakoterapijska skupina: Lijekovi za primjenu kod šećerne bolesti, kombinirani peroralni lijekovi za sniženje glukoze u krvi.
This can lead to a risk of hyperglycaemia (high blood sugar level): - oestrogens, progestogens (female sex hormones) - thiazide diuretics and saluretics also called water tablets (to treat high blood pressure) - levothyroxine (to stimulate the thyroid gland) - glucocorticoids (to treat allergies and inflammation) - chlorpromazine and other phenothiazine derivatives (to treat severe mental disorders) - adrenaline and sympathicomimetics (to increase heart beat, to treat asthma or nasal congestion,
To može dovesti do rizika od hiperglikemije (povišene razine šećera u krvi): - estrogeni, progestageni (ženski spolni hormoni) - tiazidski diuretici i saluretici koji se još zovu tablete za mokrenje (za liječenje povišenog krvnog tlaka) - levotiroksin (za stimulaciju štitne žlijezde) - glukokortikoidi (za liječenje alergija i upala) - klorpromazin i drugi derivati fenotiazina (za liječenje teških duševnih poremećaja) - adrenalin i simpatomimetici (za povećanje brzine rada srca, za liječenje astme ili začepljenosti nosa, kašlja i prehlade ili za primjenu u hitnim, životno opasnim stanjima) - nikotinska kiselina (za liječenje povišene razine kolesterola) - dugotrajna uporaba laksativa (za liječenje zatvora) - fenitoin (za liječenje napadaja) - barbiturati (za liječenje nervoze i tegoba sa spavanjem) - azetazolamid (za liječenje povišenog tlaka u oku, tj. glaukoma) - diazoksid (za liječenje povišenog tlaka u oku ili niskog šećera u krvi) - rifampicin (za liječenje infekcija, tuberkuloze) - glukagon (za liječenje jako niske razine šećera u krvi)
What Tandemact looks like and contents of the pack - Tandemact 30 mg/2 mg tablets are white to off-white, round, convex and debossed ‘4833 G' on one face and ‘30/2' on the other.
Kako Tandemact izgleda i sadržaj pakiranja - Tandemact 30 mg/2 mg tablete su bijele do gotovo bijele, okrugle, konveksne s utisnutim ‘4833 G' na jednoj strani i ‘30/2' na drugoj strani.
Localised swelling (oedema) has also been experienced commonly (may affect up to 1 in 10 people) in patients taking Tandemact in combination with insulin.
Bolesnici koji uzimaju Tandemact u kombinaciji s inzulinom često su imali lokalizirano oticanje (edeme) (može se javiti u do 1 na 10 osoba).
Any macroscopic haematuria should be investigated before starting pioglitazone therapy.
Prije početka terapije pioglitazonom nužno je provjeriti svaku makroskopsku hematuriju.
Each Tandemact 45 mg/4 mg tablet contains 45 mg pioglitazone (as hydrochloride) and 4 mg glimepiride.
- Jedna tableta lijeka Tandemact od 45 mg/4 mg sadrži 45 mg pioglitazona (u obliku pioglitazonklorida) i 4 mg glimepirida.
If you experience any of these, talk to your doctor as soon as possible.
Ako osjetite ijedan od ovih simptoma, obratite se čim prije svom liječniku.
EU/1/06/366/005 14 tablets EU/1/06/366/006 28 tablets EU/1/06/366/007 30 tablets EU/1/06/366/008 50 tablets EU/1/06/366/009 90 tablets EU/1/06/366/010 98 tablets
EU/1/06/366/005 14 tableta EU/1/06/366/006 28 tableta EU/1/06/366/007 30 tableta EU/1/06/366/008 50 tableta EU/1/06/366/009 90 tableta EU/1/06/366/010 98 tableta
EU/1/06/366/017 14 tablets EU/1/06/366/018 28 tablets EU/1/06/366/019 30 tablets EU/1/06/366/020 50 tablets EU/1/06/366/021 90 tablets EU/1/06/366/022 98 tablets
EU/1/06/366/017 14 tableta EU/1/06/366/018 28 tableta EU/1/06/366/019 30 tableta EU/1/06/366/020 50 tableta EU/1/06/366/021 90 tableta EU/1/06/366/022 98 tableta
EU/1/06/366/011 14 tablets EU/1/06/366/012 28 tablets EU/1/06/366/013 30 tablets EU/1/06/366/014 50 tablets EU/1/06/366/015 90 tablets EU/1/06/366/016 98 tablets
EU/1/06/366/011 14 tableta EU/1/06/366/012 28 tableta EU/1/06/366/013 30 tableta EU/1/06/366/014 50 tableta EU/1/06/366/015 90 tableta EU/1/06/366/016 98 tableta
Patients should be observed for signs and symptoms of heart failure, weight gain or oedema; particularly those with reduced cardiac reserve.
Bolesnike, osobito one sa smanjenom srčanom rezervom, je nužno nadzirati zbog moguće pojave znakova i simptoma zatajenja srca te povećanja tjelesne težine ili edema.
NAME OF THE MEDICINAL PRODUCT Tandemact 45 mg/4 mg tablets pioglitazone/glimepiride
NAZIV LIJEKA Tandemact 45 mg/4 mg tablete pioglitazon/glimepirid
NAME OF THE MEDICINAL PRODUCT Tandemact 30 mg/2 mg tablets pioglitazone/glimepiride
NAZIV LIJEKA Tandemact 30 mg/2 mg tablete pioglitazon/glimepirid
Very rare (may affect up to 1 in 10,000 people) - liver disease
Često (mogu se pojaviti u do 1 na 10 osoba) - povećanje tjelesne težine - omaglica - vjetrovi - infekcija dišnih puteva - utrnulost
Broken bones
Prijelom kostiju
Bladder cancer has been experienced uncommonly (may affect up to 1 in 100 people) in patients taking Tandemact.
Bolesnici koji uzimaju Tandemact manje su često razvili karcinom mokraćnog mjehura (može se javiti u do 1 na 100 osoba).
1 Moderate to severe thrombocytopenia, leucopenia, erythrocytopenia, granulocytopenia, agranulocytosis, haemolytic anaemia and pancyto-penia may occur.
1 Mogu nastati umjerena do teška trombocitopenija, leukopenija, eritrocitopenija, granulocitopenija,
Each tablet contains 45 mg of pioglitazone (as hydrochloride) and 4 mg of glimepiride.
Jedna tableta sadrži 45 mg pioglitazona (u obliku pioglitazonklorida) i 4 mg glimepirida.
Each Tandemact 30 mg/2 mg tablet contains 30 mg pioglitazone (as hydrochloride) and 2 mg glimepiride.
- Jedna tableta lijeka Tandemact od 30 mg/2 mg sadrži 30 mg pioglitazona (u obliku pioglitazonklorida) i 2 mg glimepirida.
- Tandemact 45 mg/4 mg tablets are white to off-white, round, flat and debossed ‘4833 G' on one face and ‘45/4' on the other.
- Tandemact 45 mg/4 mg tablete su bijele do gotovo bijele, okrugle, plosnate s utisnutim ‘4833 G' na jednoj strani i ‘45/4' na drugoj strani.
Each tablet contains 30 mg of pioglitazone (as hydrochloride) and 2 mg of glimepiride.
Jedna tableta sadrži 30 mg pioglitazona (u obliku pioglitazonklorida) i 2 mg glimepirida.